drugset / Trial / NCT05848440

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

NCT05848440

Phase 1 Completed 48 enrolled AstraZeneca Parexel · collab
RandomizedSequentialDouble-blindTreatment

Summary

This is a Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants.

Timeline

Start
2023-05-02
Primary completion
2023-11-13
Completion
2023-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD9550 Other / unclassified Subcutaneous